E.M. Forster: bibliography

E. M. Forster: A passage to India研究特集application/pdfdepartmental bulletin pape

Measurement of the Branching Fraction, Polarization, and CP Asymmetry for B0→ρ+ρ- Decays, and Determination of the Cabibbo-Kobayashi-Maskawa Phase ϕ2

journal articl

韓国語の副詞的成分일찍 ［ilt∫'ik］と 빨리［p'alli］の意味分析－日本語の「早（速）く」との対照の観点から－

2008-03-31departmental bulletin pape

The theme of Eden in Shakespeare

application/pdfdepartmental bulletin pape

Chaucer:The Merchant's Tale : An Exegetical Interpretation

application/pdfdepartmental bulletin pape

On Prince Hal of 1Henry IV

application/pdfdepartmental bulletin pape

A thioacetamide-induced liver fibrosis model for pre-clinical studies in microminipig

Abstract Drug-induced liver fibrosis models are used in normal and immunosuppressed small animals for transplantation and regenerative medicine to improve liver fibrosis. Although large animal models are needed for pre-clinical studies, they are yet to be established owing to drug sensitivity in animal species and difficulty in setting doses. In this study, we evaluated liver fibrosis by administering thioacetamide (TA) to normal microminipig and thymectomized microminipig; 3 times for 1 week (total duration: 8 weeks). The pigs treated with TA showed elevated blood cytokine levels and a continuous liver injury at 8 weeks. RNA-seq of the liver showed increased expression of fibrosis-related genes after TA treatment. Histopathological examination showed degenerative necrosis of hepatocytes around the central vein, and revealed fibrogenesis and hepatocyte proliferation. TA treatment caused CD3-positive T cells and macrophages scattered within the hepatic lobule to congregate near the center of the lobule and increased αSMA-positive cells. Thymectomized pigs showed liver fibrosis similar to that of normal pigs, although the clinical signs tended to be milder. This model is similar to pathogenesis of liver fibrosis reported in other animal models. Therefore, it is expected to contribute to research as a drug discovery and pre-clinical transplantation models

ROC curve validation of MGPs from the Neve training set in 5 clinical trials.

<p>In each figure, blue lines represent MGPs developed using the superPC method, while red lines represent MGPs developed using the COXEN method.</p

Distributional difference between prediction scores calculated by the superPC or COXEN methods from the Neve training set for responders (pCR, pathologic complete response) and non-responders (RD, residual disease), with p-value and AUC.

<p>In the top row, the prediction scores are calculated by the superPC method, and in the bottom row, the prediction scores are calculated by the COXEN method. Red lines represent median prediction scores in each group.</p

A Systematic Evaluation of Multi-Gene Predictors for the Pathological Response of Breast Cancer Patients to Chemotherapy

<div><p>Previous studies have reported conflicting assessments of the ability of cell line-derived multi-gene predictors (MGPs) to forecast patient clinical outcomes in cancer patients, thereby warranting an investigation into their suitability for this task. Here, 42 breast cancer cell lines were evaluated by chemoresponse tests after treatment with either TFAC or FEC, two widely used standard combination chemotherapies for breast cancer. We used two different training cell line sets and two independent prediction methods, superPC and COXEN, to develop cell line-based MGPs, which were then validated in five patient cohorts treated with these chemotherapies. This evaluation yielded high prediction performances by these MGPs, regardless of the training set, chemotherapy, or prediction method. The MGPs were also able to predict patient clinical outcomes for the subgroup of estrogen receptor (ER)-negative patients, which has proven difficult in the past. These results demonstrated a potential of using an <em>in vitro</em>-based chemoresponse data as a model system in creating MGPs for stratifying patients’ therapeutic responses. Clinical utility and applications of these MGPs will need to be carefully examined with relevant clinical outcome measurements and constraints in practical use.</p> </div